The second KRAS inhibitor 'Krazati' has been designated as an orphan drug in Korea.

The Ministry of Food and Drug Safety (MFDS) recently announced the news through the first orphan drug designation announcement of the new year.

Specifically, Krazati is indicated for 'locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have received at least one prior therapy.

BMS's Krazati (adagrasib) received accelerated approval from the U.S. FDA in December 2022. It is the second KRAS inhibitor to be approved, following Amgen's Lumakras (sotorasib), which was approved in 2021.

The development of KRAS-targeted anticancer drugs come